Evidence map›Paper›PMID 42250077›Full record

Trial reportAdvances in therapy2026

The Role of Adjuvant Corneal Cross-linking in the Management of Infectious Keratitis: An OCT-Based Assessment Study.

Shady Soliman, Dalia Said, Sundas Maqsood, Hasan Naveed, Mansour Hassan, Ahmed Atef, Mohamed Yasser Saif, Zisis Gatzioufas, Mohamed Elalfy

Registry-linked trialAbstract readRandomized Controlled TrialComparative Study
PubMed Publisher
In one paragraph

Trial report in Advances in therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06967376 (The Role of Adjuvant Cross Linking in the Management of Infective Keratitis - an OCT Based Assessment Study), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06967376 early_phase1completednot on this map

The Role of Adjuvant Cross Linking in the Management of Infective Keratitis - an OCT Based Assessment Study

TypeinterventionalSponsorResearch Institute of Ophthalmology, EgyptRan2018 to 2022Enrolled40ConditionsInfective KeratitisArmsCorneal Collagen Cross-Linking Solutions, Topical Antimicrobial/Antifungal Medications
3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shady SolimanResearch Institute of Ophthalmology, Giza, Egypt.
Dalia SaidNottingham University Hospital NHS Trust, Nottingham, UK.
Sundas MaqsoodMaidstone and Turnbridge Wells Hospital NHS Trust, Maidstone, Kent, UK.
Hasan NaveedQueen Victoria Hospital NHS Foundation Trust, East Grinstead, UK.
Mansour HassanBeni Suef University, Beni Suef, Egypt.
Ahmed AtefResearch Institute of Ophthalmology, Giza, Egypt.
Mohamed Yasser SaifBeni Suef University, Beni Suef, Egypt.
Zisis GatzioufasUniversity Hospital Basel, Basel, Switzerland.
Mohamed ElalfyResearch Institute of Ophthalmology, Giza, Egypt. m.elalfy@nhs.net.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionInfectious keratitis can lead to significant ocular morbidity and threaten vision if not treated promptly with antimicrobial therapy. Adjuvant treatment with corneal cross-linking (CXL) can improve visual outcomes in cases of infectious keratitis. Anterior segment optical coherence tomography (AS-OCT) can provide additional qualitative and quantitative information on healing.

methodsThis was a prospective, comparative control study of 40 eyes of 40 patients with infectious keratitis. The effectiveness of a customised epi-off CXL protocol was evaluated as adjuvant therapy. Clinical and AS-OCT parameters on days 7 and 14 of treatment, date of first report of healing and 1 month following reported healing were recorded.

resultsForty patients were randomly allocated to group A (medical treatment) and group B (medical treatment and CXL). The mean healing duration in days was 27.3 ± 9.27 in group A and 30.75 ± 7.39 in group B. The AS-OCT parameters corneal thickness (CT), infiltrate thickness (IT) and infiltrate width (IW) showed significant reduction compared to preoperative state with no clinically significant change between the groups (p > 0.05). The scar thickness (SC) was measured following reported complete healing and showed a statistically significant difference between the two groups (p < 0.03).

conclusionThe addition of CXL to the treatment of infectious keratitis is associated with reduced scar thickness in the healing phase. Clinically, CXL as an adjuvant therapy to the medical treatment for infectious keratitis did not improve the healing duration or the final visual outcome.

trial registrationNCT06967376 on ClinicalTrials.gov retrospectively registered on 13 May 2025.

Indexed as

Cross-Linking ReagentsKeratitisPhotosensitizing AgentsRiboflavinAdultAgedAnti-Bacterial AgentsCorneal Cross-LinkingFemaleHumansMaleMiddle AgedProspective StudiesTomography, Optical CoherenceAnti-Bacterial AgentsCross-Linking ReagentsPhotosensitizing AgentsRiboflavinAnterior segment optical coherence tomography (AS-OCT)Corneal cross-linking (CXL)Infectious keratitis

Identifiers

PMID42250077

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.